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Background: Recommendations for cardiovascular disease prevention advocate lowering both cholesterol and
low-density lipoprotein cholesterol systemic levels, notably by statin intake. However, statins are the subject of
questions concerning their impact on male fertility. This study aimed to evaluate, by a prospective pilot assay, the
efficacy and the toxicity of a decrease of cholesterol blood levels, induced by atorvastatin on semen quality and
sexual hormone levels of healthy, normocholesterolaemic and normozoospermic men.
Methods: Atorvastatin (10 mg daily) was administrated orally during 5 months to 17 men with normal plasma lipid
and standard semen parameters. Spermatozoa parameters, accessory gland markers, semen lipid levels and blood
levels of gonadal hormones were assayed before statin intake, during the treatment, and 3 months after its
withdrawal.
Results: Atorvastatin treatment significantly decreased circulating low-density lipoprotein cholesterol (LDL-C) and
total cholesterol concentrations by 42% and 24% (p < 0.0001) respectively, and reached the efficacy objective of the
protocol. During atorvastatin therapy and/or 3 months after its withdrawal numerous semen parameters were
significantly modified, such as total number of spermatozoa (−31%, p < 0.05), vitality (−9.5%, p < 0.05), total motility
(+7.5%, p < 0.05), morphology (head, neck and midpiece abnormalities, p < 0.05), and the kinetics of acrosome
reaction (p < 0.05). Seminal concentrations of acid phosphatases (p < 0.01), α-glucosidase (p < 0.05) and L-carnitine
(p < 0.05) were also decreased during the therapy, indicating an alteration of prostatic and epididymal functions.
Moreover, we measured at least one altered semen parameter in 35% of the subjects during atorvastatin treatment,
and in 65% of the subjects after withdrawal, which led us to consider that atorvastatin is unsafe in the context of
our study.
Conclusions: Our results show for the first time that atorvastatin significantly affects the sperm parameters and the
seminal fluid composition of healthy men.
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In the current context of prevention of cardiovascular risks,
a decrease of total cholesterol and low-density lipoprotein
cholesterol (LDL-C) plasma levels is an important goal for
public health [1,2]. Statins are first-choice cholesterol low-
ering agents [1,3,4]. Meta-analysis of data from randomized
controlled trials have demonstrated the higher efficiency
of statins on the incidence of cardiovascular morbidity
and mortality rates compared with other commonly used
lipid-modulating therapies [5]. Atorvastatin, the most
commonly used statin, is a synthetic, selective and com-
petitive inhibitor of 3-hydroxy-3-methyl-glutarylcoenzyme
A (HMG Co-A) reductase. At the molecular level, statins
inhibit cholesterol [6] as well as dolichol and coenzyme
Q10 [7,8]. Decreased coenzyme Q10 concentration de-
creases sperm motility, number of spermatozoa, vitality
and increases sperm pathology [8,9].
Sterols are essential in male reproductive physiology,
notably for steroidogenesis, spermatogenesis and fertilization
[10-12]. During spermatogenesis and epididymal matur-
ation, spermatozoa must undergo a major remodeling of
their membrane lipid composition and distribution to
acquire progressive motility, final morphology and abil-
ity to achieve capacitation and acrosome reaction in the
female genital tract [13]. Cholesterol efflux from the
plasma membrane is a precursor event of capacitation
[14-16], leading to the activation of specific intracellular
signal transduction pathways [17-19]. Only capacitated
spermatozoa are able to undergo an acrosomal reaction
in contact with the zona pellucida before fertilizing the
oocyte [20].
Since lipid metabolism disorders are associated with im-
paired fertility [21] or altered sperm parameters [22], in
theory statins could permit improvement in sperm param-
eters in a context of dyslipidemia. However, concern has
always existed that statins might impair testosterone pro-
duction [23] and potentially affect testicular sperm pro-
duction and/or quality. In fact, in the scientific and
medical literature, the effects of statin therapy on steroid
levels and sperm parameters in hypercholesterolaemic
men are very heterogeneous, depending on dosage, popu-
lation and comorbidity context [23-34]. Furthermore, for
the past 30 years, studies concerning statins have rarely
been exhaustive regarding male fertility, focusing more on
steroidogenesis impact than on semen quality. Recently,
concerns have been raised about the effect of atorvastatin
intake on sperm quality [35]. The most commonly used
statin, atorvastatin has never been investigated regarding
its influence on male fertility, notably on semen quality.
This study is a prospective pilot assay that evaluates
the efficacy and the toxicity of a decrease of cholesterol
blood levels induced by atorvastatin on the fertility of
healthy men without confounding factors. For the first
time the effects of atorvastatin were analyzed on humansperm parameters, accessory gland secretions, semen
lipid composition and testosterone and gonadotropins




Volunteers were recruited in accordance with the 1975
Helsinki declaration on human experimentation, under a
protocol approved for research by a Regional Ethical
Committee and the French Agency for the Safety of
Health Products (AFSSAPS) and was registered in
Clinical Trials Register with the identifier number: NCT
02094313. Written informed consent was obtained from
subjects before inclusion in the study.
Trial design and subjects
The main objective of this pilot study was to estimate the
toxicity and the efficacy of atorvastatin on fertility of
normocholesterolaemic and normozoospermic men by
analyzing its effects on sperm parameters. The secondary
objective was to assess the evolution of gonadotropins and
total testosterone plasma levels, lipid composition of
sperm cells and seminal fluid, spermatozoa capacitation
ability and accessory glands markers.
Inclusion criteria were healthy men, 18 to 65 years old,
with normal conventional semen parameters and negative
semen culture according to the 1999 WHO standards [36]
and to David’s criteria for morphology [37], with normal
blood lipid profile (total cholesterol < 2.50 g/L, triglycer-
ides < 1.70 g/L, HDL-C > 0.35 g/L and LDL-C < 2.2 g/L)
and without known disease or ongoing treatment. Non-
inclusion criteria were subjects having a surgical or med-
ical history that might contra-indicate the study, liver
disease, prolonged elevation of serum transaminases, lipid
parameters not matching with the inclusion criteria, ab-
normal semen parameters, positive semen culture, crypt-
orchidism, varicocele, receiving lipid-lowering therapy, or
lastly, subjects participating in another clinical study or
another experiment over a shorter period than the period
of exclusion.
Considering this protocol as a pilot study to evaluate
toxicity and efficacy, sample size estimation was fixed
according to a one-/multi-stage Fleming design. This de-
sign with one group and multi-stages (between 1 and 5)
can be seen as filtering steps leading to the “go/no go”
decision type. They are among those most used in phase
II trials in oncology but remain far more rarely imple-
mented in other areas [38].With type I error α and stat-
istical power (1-β) values of 5% and 90% respectively, 17
subjects were necessary to reject the hypotheses of min-
imal (p = 0.85) and maximal (p = 0.95) acceptable non-
toxicity. If one subject or more presented toxicity, the
treatment was considered unsafe.
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of atorvastatin on sperm parameters according to the 1999
WHO standards [36] (ejaculate volume < 2 ml, sperm
count < 20 millions/ml, total motility < 50%, progressive
motility < 30%), to David’s criteria for morphology [37] (typ-
ical forms < 20%) and to BIOFORMA guidelines [39] for
accessory gland markers (fructose ≥ 20 μmol per ejaculate,
citric acid ≥ 60 μmol per ejaculate, acid phosphatases ≥ 1234
UI per ejaculate, neutral alpha 1,4 glucosidase ≥ 59 mU per
ejaculate, L-carnitine ≥ 390 nmol per ejaculate).
The efficacy was estimated by measuring the lipid lower-
ing action of atorvastatin with expected final levels < 1.5 g/L
and < 1 g/L for total cholesterol and LDL-cholesterol re-
spectively, or decreases by 20 and 40% of initials levels of
total cholesterol blood and LDL-cholesterol, respectively.
To measure the evolution of these parameters 17 subjects
were necessary to show the efficacy with a minimal paired
difference to be detected of 0.5, with expected standard-
deviation of difference of 0.5, correlation coefficient of 0.5,
and α value of 5% (two-sided) for a power greater than
90% (1-β = 97%).
Thirty-nine subjects were assessed for eligibility (Flow
Diagram is presented in Additional file 1: Figure S1).
During the screening visit (visit 0), routine laboratory bio-
chemical tests were carried out, an electrocardiogram was
performed, blood pressure, weight and height were mea-
sured; physical examination including testis evaluation and
semen parameters were analyzed in the Biology of
Reproduction Laboratory of the University Hospital of
Clermont-Ferrand according to the 1999 WHO standards
[36]. Finally, 17 subjects (mean age 24.4 ± 0.9 years) with
normal lipid semen parameters were included. The subjects
took atorvastatin orally (10 mg/day (d), Tahor©, Pfizer La-
boratory) during 5 months allowing the study of atorva-
statin effects on human spermatogenesis and epididymal
maturation (one cycle requiring approximately 3 months
and maximal efficacy of atorvastatin reached within
4 weeks). Blood and semen parameters were measured be-
fore (visit 1), during the 5 months of atorvastatin treatment
(visit 3), and 3 months after the end of treatment (visit 4),
to perform measurements during different cycles of sperm-
atogenesis on a same subject. Biochemical clinical and
semen measurements made before treatment were consid-
ered as “control baseline measures”. After two months of
treatment, a consultation (visit 2) took place to ensure good
tolerance of treatment and to control treatment efficiency.
Chemicals
All chemicals were purchased from Sigma-Aldrich (St Quentin
Fallavier, France), unless otherwise indicated.
Biochemical analyses on blood
Blood was kept on ice in heparin-coated tubes and then
centrifuged 15 min at 1500 g at 4°C. Assays were performedon an automated clinical chemistry analyzer (Hitachi
Modular; Roche Diagnostics, Meylan, France) based on
enzymatic colorimetric (triglycerides, total cholesterol,
HDL-C, LDL-C) or electrochemiluminescence assays (total
testosterone, FSH, LH) according to the manufacturer’s
instructions.
Semen parameter measurements
The ejaculates were collected by masturbation after 3 to
5 days of abstinence. Immediately after liquefaction semen
parameters were evaluated according to the WHO guide-
lines, 1999 [36]. Sperm morphology was studied according
to David’s criteria with the evaluation of Multiple Anomal-
ies Index (MAI) [37]. Sperm motion analysis was realized
with a Hamilton-Thorn Sperm Analyzer (HTM Ceros
model 12, Hamilton-Thorn Biosciences, Beverly, MA,
USA) as previously described [40]. Seminal levels of fruc-
tose (seminal vesicle marker), acid phosphatases and citric
acid (prostate markers), and α-glucosidase and L-carnitine
(epididymal markers) were measured by colorimetric as-
says as described in the WHO guidelines [36], BIOFORMA
guidelines [39] and in a previous work [41].
For semen lipid determination, samples were centri-
fuged at 500 g for 5 min. The resulting pellet containing
the sperm cells was washed twice in Phosphate-buffered
Saline (PBS) by centrifugation (500 g, 5 min). The
supernatant corresponding to seminal fluid was centri-
fuged (15 min, 10,000 g, 4°C) to remove cell debris.
Lipids present in spermatozoa and in seminal fluid were
extracted following a modified Folch procedure [42].
The phospholipids and sterols were separated by high
performance thin layer chromatography (HPTLC) using
a sequential development system as described in a prior
study [43].
Capacitation was estimated by measuring two signal-
ing pathway markers. The first marker, is the early chol-
esterol redistribution in sperm membranes [44,45]. The
second involves the phosphorylation of tyrosine resi-
dues (P-Tyr) of terminal protein markers P80 and P110
of cAMP - protein kinase A (PKA) signal pathway.
Cholesterol redistribution in sperm membranes was es-
timated by epifluorescence microscopy (×400) using
filipin, as indicated in prior studies [44,45]. Sperm cells
with a marked fluorescence in the acrosome region (fili-
pin positive spermatozoa) are not capacitated, while ca-
pacitated sperm cells show no fluorescence in the head
(filipin negative spermatozoa). For P-Tyr and acrosome
integrity assays, spermatozoa were selected using a two-
step discontinuous Percoll - HEPES-buffered saline gra-
dient 80-40% (30 min, 1000 g). The 80%-fraction was
washed once by centrifugation (500 g, 5 min) in modi-
fied Biggers–Whitten–Whittingham medium supple-
mented with 3 mg/ml BSA and was then incubated in
capacitating conditions (37°C, 5% CO2). P-Tyr and
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incubation. P-Tyr of P80 and P110 proteins, was monitored
by western-blot using a monoclonal anti-phosphotyrosine
antibody (clone 4G10; Upstate Biotechnology Inc, Lake
Placid, NY) and a mouse monoclonal anti α-tubulin
antibody as indicated in a prior study [46]. The phos-
photyrosine signal was normalized to the tubulin signal
(Figure 1B and C). The ratios were then related to those
obtained before incubation. Acrosome integrity was esti-
mated after spermatozoa fixation, permeabilization in 98%
methanol (30 min, − 20°C), and labeling with a freshly
prepared solution of Pisum sativum agglutinin conjugated
to fluorescein isothiocyanate (PSA-FITC, 60 μg/ml final)
in PBS. Sperm cells were observed blindly using epifluor-
escence microscopy (×400). Sperm cells with an intact ac-
rosome membrane show a marked fluorescence in the
acrosome region (A pattern, Figure 1D), while those hav-
ing lost their acrosome membrane are devoid of fluores-
cence or display a marked fluorescence along the
equatorial segment (AR pattern, Figure 1D).
Statistics
Statistical analyses were performed with Prism 6 (Graph-
Pad Software) using parametric paired tests. The different
parameters measured during and 3 months after the end
of atorvastatin treatment were compared with initial values
(control baseline values), by one-way paired ANOVA with
Holm-Sidak multiple comparison post-test when the distri-
bution was normal; if not we applied a nonparametric
post-test (Dunn’s Multiple Comparison Test). For each
comparison, the corresponding effectiveness was checked
to verify the robustness of the analysis.
Results
Baseline clinical and biochemical characteristics of studied
subjects are summarized in Tables 1 and 2. All the subjects
were healthy men between 20 and 38 years old (Table 1),
with normal renal, hepatic and cardiac functions, body
mass index (Table 1) and serum lipid parameters (Table 2)
and without known pathology or ongoing treatment. Dur-
ing the 5-month atorvastatin intake period, 15 subjects had
a total cholesterol serum level < 1.5 g/L and 16 subjects
had a LDL-cholesterol level < 1 g/L, achieving the protocol
efficacy goal. We measured a significant decrease of both
total cholesterol (−24%, p < 0.0001, Table 2) and LDL-C
(− 42%, p < 0.0001, Table 2) blood mean levels. Three
months after atorvastatin withdrawal, values of total chol-
esterol and LDL-C were comparable to those observed be-
fore treatment. The serum levels of triglycerides, HDL-C,
testosterone, FSH and LH were not affected by atorvastatin
(Table 2), nor were the measured blood, hepatic, renal and
cardiac markers (data not shown).
The reduction of cholesterol level in serum did not
significantly affect semen cholesterol and phospholipidlevels, whether in spermatozoon or in seminal fluid
(Table 3). However, we noted that the cholesterol/phos-
pholipids ratio tended to decrease both in sperm cells
and in seminal fluid during the treatment.
Mean values of semen parameters were significantly al-
tered by atorvastatin intake (Table 3). Total sperm num-
ber (−31%) and vitality (−9.5%) were significantly reduced,
notably after treatment withdrawal (p < 0.05). The terato-
zoospermia Multiple Anomalies Index (MAI) and the
number of head, neck and midpiece abnormalities were
significantly increased (p < 0.05), even if the proportion of
morphologically abnormal spermatozoa was not globally
modified. Conversely, total motility was slightly but sig-
nificantly improved during treatment (65.5 ± 2.2% during
vs. 60.9 ± 1.8% before, p < 0.05), with no effect either on
progressive motility or on sperm motion parameters.
When the effects were analyzed per subject, 2 out of 17
men were necro- and asthenozoospermic according to
the WHO 1999 standards, notably after withdrawal of
treatment (Figure 2A and B), exceeding the safety limits
of the study.
Markers of the accessory sex glands were also per-
turbed. The amount of prostatic acid phosphatases was
significantly reduced 3 months after atorvastatin with-
drawal (p < 0.01 vs. control value, Figure 3B). Similarly, the
levels of epididymal neutral α-glucosidase and L-carnitine
were significantly decreased (p < 0.01 and p < 0.05 for
α-glucosidase and L-carnitine, respectively, Figure 3C).
Regarding individual impact, one patient presented an ab-
normal value for neutral α-glucosidase (6% value, < 59 mU,
Figure 3D) before the beginning of treatment according to
BIOFORMA standards. During the treatment 35% (6 sub-
jects) showed altered activity of neutral α-glucosidase with
a mean value of 40.0 ± 7.6 mU. Three months after the
end of therapy, more than half of the subjects presented
an abnormal value of neutral α-glucosidase (53%, 9 sub-
jects Figure 3D) with an activity mean of 43.8 ± 7.8 mU.
Atorvastatin effects on neutral α-glucosidase again
exceeded the safety limits fixed by the study.
To further evaluate the fertilizing ability of spermato-
zoa, capacitation and acrosome reaction were measured
in capacitating conditions. Spermatozoa capacitation was
evaluated by measuring early markers such as choles-
terol depletion from plasma membrane and terminal
markers of signaling pathways corresponding to the P-
Tyr levels of proteins P80 and P110. Atorvastatin treat-
ment had no effect on the proportion of filipin negative
spermatozoa (Figure 1A) nor on the P-Tyr level of
the two protein markers of capacitation P110 and P80
(Figure 1B and C). However, it was observed that the
level of P-Tyr tended to increase during treatment and
3 months after atorvastatin withdrawal. The proportion
of spontaneous acrosome-reacted (AR, Figure 1D)
spermatozoa tended to be reduced by the cholesterol-
Figure 1 Atorvastatin effects on membrane cholesterol distribution, P-Tyr and acrosome reaction in spermatozoa. Membrane cholesterol
distribution, P-Tyr and acrosome integrity were analysed in spermatozoa obtained from 17 normocholesterolaemic men before, during and
3 months after the end of treatment as described in Methods. P-Tyr patterns were assessed before (t = 0 h) and after (t = 3 h) incubating
spermatozoa in capacitating conditionsd and visualized by western blotting using a monoclonal anti-phosphotyrosine antibody. To calibrate
the signal for the amount of sperm protein, the same membranes were reprobed using a monoclonal anti-alpha-tubulin antibody. Acrosome
integrity was assessed before (5 min) and after 3 h of incubation in capacitating conditions (3 h), by epifluorescence microscopy (x400) using
PSA-FITC as a probe. A represents mean ± SEM of the percentage of sperm cells showing a redistribution of cholesterol with filipin labelling
absent in the sperm head. Cholesterol distribution was estimated by epifluorescence microscopy (x400) using filipin as a probe. B represents
typical patterns of protein tyrosine phosphorylation (P-Tyr) and α-tubulin in human spermatozoa. C represents P-Tyr signal normalized to the
tubulin signal and the ratios were related to the basal signal obtained before incubation. Data are represented as mean ± SEM in arbitrary units
(a.u.). D represents a fluorescence micrograph showing a sperm cell with an intact acrosome membrane (A pattern: marked fluorescence in the
acrosome region) and a sperm cell without an acrosome membrane (AR pattern: no fluorescence or marked fluorescence along the equatorial
segment). E represents mean ± SEM of the percentage of AR spermatozoa. *indicates values significantly different from those measured before
atorvastatin intake with p < 0.05.
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fore treatment, 5 min, Figure 1E) and after 3 h of incu-
bation under capacitating conditions (28.3 ± 7.4% vs.
36.1 ± 8.5% before atorvastatin intake, Figure 1E). This
trend was also observed 3 months after the end of the
therapy and became significant for the AR proportion
obtained after 3 h of incubation under capacitating
conditions (12.3 ± 2.0%, p < 0.05 in comparison with
values before atorvastatin treatment).Discussion
This is the first study evaluating atorvastatin effects on
semen quality and testicular steroidogenesis regulation
in normocholesterolaemic, young and healthy men. This
work is a prospective non-controlled pilot assay evaluat-
ing atorvastatin efficacy and toxicity on human semen
parameters. A 5-month atorvastatin intake (10 mg/d) in-
duced a significant decrease in serum levels of total
cholesterol and LDL-C achieving the efficacy goal of the
Table 1 Baseline clinical characteristics of studied
subjects
Baseline clinical characteristics
Number of subjects 17
Age (years) 24.35 ± 0.99
BMI 22.74 ± 0.58
Systolic BP (mmHg) 123.53 ± 2.70
Diastolic BP (mmHg) 77.94 ± 0.96
Serum creatinine (μmol/L) 86.76 ± 2.43
Serum glucose (mmol/L) 5.1 ± 0.09
Red blood cells (T/L) 5.1 ± 0.06
Hemoglobin (g/dL) 14.87 ± 0.15
Hematocrite (%) 43.76 ± 0.4
Platelets (G/L) 224.53 ± 9.62
Leukocytes (G/L) 5.75 ± 0.32
Polynuclear neutrophils (G/L) 2.87 ± 0.25
Polynuclear eosinophils (G/L) 0.16 ± 0.03
Polynuclear basophils (G/L) 0.02 ± 0.00
Lymphocytes (G/L) 2.15 ± 0.14
Monocytes (G/L) 0.54 ± 0.04
SGOT (IU/L) 25.65 ± 1.46
SGPT (IU/L) 25.89 ± 3.57
CK (IU/L) 137.88 ± 22.45
GGT (IU/L) 20.82 ± 1.63
Data are presented as the mean ± SEM. BMI: Body Mass Index; BP: blood
pressure; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum
glutamic-pyruvic transaminase, CK: Creatine kinase, GGT: Gamma-glutamyl
transpeptidase.








Serum levels of lipids
Total cholesterol (g/L) 1.67 ± 0.08 1.27 ± 0.07*** 1.71 ± 0.08
Triglycerides (g/L) 0.83 ± 0.06 0.73 ± 0.11 0.93 ± 0.14
HDL-C (g/L) 0.53 ± 0.03 0.52 ± 0.03 0.51 ± 0.03
LDL-C (g/L) 0.98 ± 0.07 0.57 ± 0.05*** 0.98 ± 0.07
Serum levels of hormones
FSH (UI/L) 2.85 ± 0.30 2.87 ± 0.33 2.89 ± 0.30
LH (UI/L) 4.47 ± 0.54 5.00 ± 0.37 4.57 ± 0.35
Total testosterone (nmol/L) 22.71 ± 1.56 24.04 ± 1.99 22.81 ± 1.71
Data are presented as mean ± SEM. Seventeen normocholesterolaemic men
received 10 mg/d atorvastatin during 5 months as described in Methods. The
serum levels of total cholesterol, triglycerides, HDL-C, LDL-C, FSH, LH and total
testosterone were measured before, during and 3 months after the end of
treatment. ***indicates values significantly different from those obtained
before treatment with p < 0.001.
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ters significantly. It also decreased the total number of
spermatozoa in ejaculate and sperm vitality, increased
morphological abnormalities and total motility, and al-
tered acrosome reaction kinetics. Seminal concentrations
of acid phosphatases, α-glucosidase and L-carnitine were
also decreased. All these results hint at deleterious ef-
fects of atorvastatin on testicular, prostatic and epididy-
mal functions.
At the end of the study, 9 subjects (53%) had an alter-
ation of at least one semen marker; two men were
necro-asthenozoospermic and had a low value of neutral
α-glucosidase. We had specified that if one subject or
more presented toxicity on sperm or accessory gland
markers, the treatment was considered unsafe. The re-
sults obtained led to the decision to stop the protocol
and to conclude in the efficacy but also the toxicity of
atorvastatin for semen parameters. To further evaluate
the fertilizing ability of spermatozoa, capacitation and
acrosome reaction were measured in capacitating condi-
tions. To our knowledge, fertilizing ability has never
been studied in the context of a cholesterol-lowering
therapy in humans. Atorvastatin had no significant effect
on early (cholesterol depletion from plasma membrane)
or terminal markers (P-Tyr levels of proteins P80 and
P110) [19,47] of capacitation. Nevertheless, the propor-
tion of acrosome-reacted spermatozoa was significantly
decreased by atorvastatin intake.
Our study showed that atorvastatin therapy does not
alter cholesterol and phospholipid composition of
human spermatozoa and seminal fluid. This is consistent
with our previous study showing that normo- and
hypercholesterolaemic men had similar amounts of
cholesterol and phospholipids in semen [41]. The same
observations were made in the rabbit [48-50], with, how-
ever, a modification of sterol distribution in acrosome
and plasma membranes, and significant alterations of
sperm parameters. In our study, we did not observe any
significant modification of cholesterol distribution in the
human sperm head as shown by filipin fluorescence,
even if acrosome reaction kinetic was slightly altered.
These discrepancies could be explained by differences in
cholesterol regulation between the different models.
Nevertheless, we can exclude yhe postalte that atorvastatin
could affect other sterols in the human sperm membrane.
Similarly, modifications of systemic cholesterol metab-
olism do not significantly modify cholesterol and
phospholipid levels in semen. These data could explain
the absence of effects of atorvastatin on systemic levels
of total testosterone and gonadotropins. Nevertheless,
sperm production and quality were decreased and pros-
tatic and epididymal markers were altered. Such data in-
dicate clearly that atorvastatin therapy affects testicular,
epididymal and prostatic functions. Testis, epididymis
Table 3 Effects of atorvastatin on human semen








Semen volume (ml) 3.9 ± 0.4 4.0 ± 0.6 3.5 ± 0.4
Semen pH 8.0 ± 0.1 7.9 ± 0.1 8.1 ± 0.2
Sperm concentration
(106 spz/ml)
146.1 ± 17.8 119.1 ± 15.6 109.9 ± 14.8
Sperm number
(106 spz/ejaculate)
540.5 ± 83.3 449.1 ± 75.6 375.0 ± 60.5*
Vitality (%) 85.2 ± 1.5 78.8 ± 1.7** 77.1 ± 2.7*
Total motility (%) 60.9 ± 1.8 65.5 ± 2.2* 62.7 ± 2.5
Progressive motility (%) 57.9 ± 1.8 58.6 ± 2.2 58.0 ± 2.8
VSL (μm/s) 50.4 ± 2.9 47.5 ± 1.5 50.6 ± 2.5
VCL (μm/s) 84.6 ± 2.5 80.8 ± 2.3 87.1 ± 3.2
Linearity (%) 61.1 ± 2.2 58.8 ± 1.4 57.9 ± 2,0
ALH (μm) 3.7 ± 0.2 3.6 ± 0.1 3.8 ± 0.2
Sperm abnormalities (%) 64.5 ± 2.6 63.5 ± 2.4 66.4 ± 2.4
Head abnormalities 66.1 ± 4,0 64.8 ± 3.5 73.5 ± 4.6‡
Excess residual cytoplasm 3.1 ± 0.6 5.8 ± 1.3 5.2 ± 0.9
Neck and midpiece
abnormalities
13.3 ± 1.9 13.0 ± 2.2 17.7 ± 1.7*
Tail abnormalities 6.6 ± 1.0 4.7 ± 0.8 6.9 ± 1.2
MAI 1.6 ± 0.18 1.41 ± 0.03 1.54 ± 0.05‡‡
Cholesterol and phospholipid concentrations in Spermatozoa (nmol/108)
Cholesterol 80.94 ± 6.08 95.47 ± 9.88 93.32 ± 8.09
PE 50.46 ± 6.10 61.82 ± 6.32 57.37 ± 6.91
PC 120.55 ± 17.84 158.00 ± 18.09 142.97 ± 16.83
SM 34.48 ± 4.11 42.56 ± 6.47 32.61 ± 2.42
Cholesterol/(PE +
PC + SM) ratio
0.46 ± 0.04 0.39 ± 0.03 0.44 ± 0.05
Cholesterol and phospholipid concentrations in Seminal fluid (μmol/ml)
Cholesterol 34.38 ± 2.55 35.24 ± 3.00 34.48 ± 3.33
PE 5.52 ± 0.64 6.10 ± 0.73 7.95 ± 1.75
PC 6.95 ± 0.78 7.21 ± 0.95 7.90 ± 2.09
SM 12.58 ± 1.38 12.71 ± 1.42 12.07 ± 1.14
Cholesterol/(PE +
PC + SM) ratio
1.44 ± 0.06 1.40 ± 0.06 1.36 ± 0.07
Data are presented as the mean ± SEM. Seventeen normocholesterolaemic
men received 10 mg/d atorvastatin during 5 months as described in Methods.
The semen parameters and cholesterol and phospholipid concentrations were
measured before (control baseline values), during and 3 months after the end
of treatment.
VSL: straight line velocity; VCL: curvilinear velocity; ALH: amplitude of lateral head
displacement; MAI: Multiple Anomalies Index; PE: phosphatidylethanolamine;
PC: phosphatidylcholine; SM: sphingomyelin. *and **indicate that the value is
significantly different from those obtained before treatment with p < 0.05 and
p < 0.01 respectively. ‡ and ‡‡ indicate that the value is significantly different from
the value measured during atorvastatin uptake with p < 0.05 and
p < 0.01 respectively.
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http://www.rbej.com/content/12/1/65[51,52] and prostate [53] are androgen-dependent or-
gans. Epididymal secretion of α-glucosidase, specifically,
is androgen - dependent [54,55]. Since gonadotropin
and testosterone plasma levels were not affected, we can
exclude a direct effect of peripheral blood sexual hor-
mones. Furthermore, the main income of testosterone in
the epididymis is through the efferent ducts [51,52]. An
hypothesis could be that atorvastatin induced a local
and minor alteration of testosterone and/or dihydrotes-
tosterone (DHT) homeostasis in the genital tract that
does not impact testosterone and gonadotropin systemic
levels. Epididymal, testicular or spermatic cord blood
measures of androgen levels are difficult to perform in
the humans to verify this hypothesis. Maybe the seminal
fluid assays of testosterone and DHT would be indica-
tive. Use of animal models could also allow deepening
the effect of atorvastatin on male genital tract and notably
on testicular steroïdogenesis. This should allow at least a
measurement of the intratesticular level of androgens.
We could also consider that atorvastatin might induce
local inflammation or oxidative stress with persistent ef-
fects on prostatic and epididymal secretion. A recent
study has characterized prostatic acid phosphatases regu-
lation in androgen-dependent and -independent manner
[56], suggesting that it could be considered that statin ef-
fects on the genital tract could be more complex than an
androgen-mediated action. Moreover, most of the effects
of atorvastatin were observed 3 months after stopping the
treatment, despite the return of cholesterol and LDL-C to
normal levels. It would have been interesting to follow the
subjects for a longer time after atorvastatin withdrawal to
determine when the parameters returned to baseline.
This persistent effect could indicate that atorvastatin
effects on the genital tract could be also mediated by a
messenger or an intermediary that persists after the end
of therapy. In 2005, Niederberger raised the question of
the adverse effect of atorvastatin on human fertility [35].
One hypothesis to explain this action is that atorvastatin
induces a decrease in ubiquinone oxido-reductase (Co-
enzyme Q10) level. The enzyme represents an important
intracellular antioxidant for spermatozoa in the seminal
fluid and its concentration in seminal fluid is positively
correlated with sperm motility [57,58]. Recently, it was
proposed that statins could act by three major intracellular
mechanisms implicating insulin signaling transduction
pathway, ATP and calcium regulation [8]. Atorvastatin
could also affect important downstream products such as
Coenzyme Q10, farnesyl pyrophosphate, geranylgeranyl
pyrophosphate, and dolichol. A last hypothesis could be
that atorvastatin acts via these different products leading
to alterations of intracellular signaling pathways in genital
tract tissue or sperm cells, associated or not with an oxi-
dative stress. Once again, animal models could be an
Figure 2 Effects of atorvastatin on human sperm vitality and progressive motility. Percentages of viable (A) and total motile (B) spermatozoa
of the seventeen subjects are represented in the spider graphs before (control baseline values), during and 3 months after the end of treatment.
*indicates patients having altered sperm parameters according to WHO standards.
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http://www.rbej.com/content/12/1/65interesting perspective to characterize atorvastatin effects
on the genital tract.
A major deleterious effect of atorvastatin was observed
on secretory gland markers, notably on epididymal markers.
Purvis et al., in 1992 ([23,59], Additional file 2: Table S1)
measured no effect of simvastatin intake (3.5 months at
40 mg/d) on human accessory gland markers. However, it
was established that statins can affect the prostate, notably
prostate-specific antigen (PSA) serum levels [60,61], and
can act within prostate cell membrane on discrete regions
known as lipid rafts [6,62]. Furthermore it was demon-
strated that statins, notably simvastatin, have an effect on
the synthesis and secretion of cholesterol by human
PC3prostate cancer cells via prostasomes [63,64]. In con-
trast to acid phosphatases, the seminal levels of citric acid
(another prostate marker) and sterols (whose main source
is the prostate) remained unchanged. These data suggest
that atorvastatin could affect specifically the synthesis
and/or the secretion of acid phosphatases, possibly by tar-
geting specific prostatic cells or by a specific signaling
pathway. A previous study has demonstrated that the
seminal L-carnitine level was significantly increased in
men with hypercholesterolemia [41]. The epididymis is
the site of sperm maturation and acquisition of linear and
progressive motility. We found moderate but significant
changes in the morphology and motility of sperm, in ac-
cordance with an effect of atorvastatin on the primary
functions of the epididymis.
The main objective of this study was to determine spe-
cific effects of atorvastatin intake on semen parameters
and hormonal regulation of young men in the context of
secondary cardiovascular prevention. Previous studies (fordetails see Additional file 2: Table S1) have shown deleteri-
ous effects of simvastatin or pravastatin on human sperm
parameters [65-67]. A few others measured no effect of
pravastatin or simvastatin intake on sperm quality [28,59].
In all these studies, statin effects were of low amplitude
and values measured after therapy remained within nor-
mal values, indicating no clinical deleterious impact on
human sperm quality.
Similarly, some authors reported an association between
statin therapy and hypogonadism [25,27,33,34,60,68], while
others did not, notably at low or moderate doses (between
10 and 40 mg/d) of simvastatin [29,59,65], pravastatin
[28,29,65,66,69,70], lovastatin [67] or atorvastatin [30,71].
Since these different statins have different hydrophilic
properties, it cannot be excluded that their pharmacoki-
netic or physicochemical properties have an impact on
their effects. Recently, a meta-analysis of placebo random-
ized controlled trials of statins demonstrated that statin
therapy decreased testosterone by 0.66 in middle-aged
men with hypercholesterolemia [23]. Nevertheless, this
average change is limited, while the range of normal values
for testosterone is quite wide. Moreover, male hypogonad-
ism and dyslipidaemia have been associated with different
concomitant morbid factors including age, renal disease,
type 2 diabetes, obesity, liver cirrhosis, metabolic syndrome
or erectile dysfunction [23,30,31,33,68,72-76]. These co-
morbidity factors could be confounding elements and, at
least partially, responsible for the deleterious effects on an-
drogen regulation and sperm quality. In this study, we
measured the effects of statins on the fertility of young,
healthy and normocholesterolaemic subjects without con-
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Figure 3 Atorvastatin effects on markers of the accessory sex glands. The seminal levels of fructose (A) (seminal vesicle marker), acid
phosphatases and citric acid (B (prostate markers), and alpha-glucosidase and L-carnitine (C and D) (epididymal markers) were measured in 17
normocholesterolaemic men before, during and 3 months after the end of treatment, as described in Methods. In A, B and C, bar represents
mean ± SEM. **indicates values significantly different from those obtained before atorvastatin intake with p < 0.01 and ‡ indicates values
significantly different from those measured during atorvastatin treatment with p < 0.05. In D, bars (white and coloured) and symbols (points and
squares) represent mean ± SEM and percentages respectively of the subjects having normal (white) and altered (coloured) values of neutral
α-glucosidase activity before, during and 3 months after the end of treatment.
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http://www.rbej.com/content/12/1/65effects of statins on healthy men, and only steroidogenesis
was explored [77].
Our work demonstrates that atorvastatin therapy, at
10 mg daily, had no effect on total testosterone and go-
nadotropin serum level but affected significantly sperm
parameters of young and healthy men and was considered
as deleterious in the context of our protocol. Yet, in view
of our results in this young population, it may beconsidered that the effects could be more pronounced
among older men specifically if less healthy. For this pilot
assay, control baseline values were measured for each sub-
ject before the beginning of the atorvastatin treatment, ra-
ther than include a placebo-treated group allowing us to
limit the high inter-individual variability and to include a
relatively small numbers of subjects. A perspective will be
to perform a randomized placebo-controlled assay with a
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http://www.rbej.com/content/12/1/65larger cohort and a longer study time to confirm and
deepen atorvastatin effects on men fertility.
Conclusions
In conclusion, our study shows for the first time that the
intake of atorvastatin by healthy and normocholesterolae-
mic subjects significantly affected their sperm parameters
(vitality, number, motility, morphology and acrosome re-
action) and changed their seminal fluid composition.
These consequences occurred after only 5 months of
treatment. Considering the long duration of statin treat-
ment, for which the clinical benefit with respect to cardio-
vascular diseases is beyond question, potential negative
consequences on reproductive function should be taken
into account when deciding to initiate such a treatment,
notably for young adults.
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